<DOC>
	<DOCNO>NCT00080743</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes necessary growth . Hormone therapy use tamoxifen may fight breast cancer block use estrogen tumor cell . Combining gefitinib tamoxifen may effective kill tumor cell become resistant ( stopped respond ) tamoxifen . PURPOSE : This randomized phase II trial study well give gefitinib together tamoxifen work compare gefitinib alone treat patient metastatic breast cancer stop respond tamoxifen .</brief_summary>
	<brief_title>Gefitinib With Without Tamoxifen Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare rate clinical benefit patient tamoxifen-resistant breast cancer treat gefitinib without tamoxifen . Secondary - Determine toxic effect regimens patient . - Determine whether change fludeoxyglucose F 18 uptake positron emission tomography scan change plasma DNA level indicator early response gefitinib patient . - Determine pharmacokinetics regimens patient . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord population ( intent-to-treat population comprise patient receive 1 dose treatment vs subset intent-to-treat population , exclude patient nonmeasurable/evaluable disease ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral tamoxifen daily . Beginning 14 day start tamoxifen , patient receive oral gefitinib daily . - Arm II : Patients receive oral placebo daily . Beginning 14 day start placebo , patient receive oral gefitinib arm I . In arm , treatment continue 26 week absence disease progression unacceptable toxicity . Patients follow 6 month . PROJECTED ACCRUAL : A total 46 patient ( 23 per treatment arm ) accrue study within 23 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Metastatic disease Initial clinical benefit tamoxifen metastatic disease , define 1 following : Stable disease 24 week longer Objective tumor response Documentation clinical progression tamoxifen within past 6 week Hormone receptor status : Estrogen progesterone receptor positive recently analyze biopsy PATIENT CHARACTERISTICS : Age 18 Sex Not specify Menopausal status Not specify Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Renal Creatinine ≤ 1.5 time ULN OR Creatinine clearance ≥ 50 mL/min Pulmonary No clinically active interstitial lung disease Patients asymptomatic chronic stable radiographic change eligible Other Not pregnant nursing Fertile patient must use effective contraception No known hypersensitivity gefitinib No malignancy within past 5 year except basal cell carcinoma carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent trastuzumab ( Herceptin® ) Chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy See Disease Characteristics At least 2 week since prior tamoxifen No concurrent hormone replacement therapy No concurrent antiestrogens , include raloxifene No concurrent aromatase inhibitors No concurrent megestrol Concurrent systemic steroid reason skin toxicity allow provided steroid initiate study entry AND dose remain stable Radiotherapy Concurrent palliative radiotherapy shortterm treatment symptomatic bone metastasis allow provide evaluable site disease present AND treatment last 14 day Surgery Recovered prior oncologic major surgery No concurrent surgery 7 day study treatment No concurrent ophthalmic surgery Other Recovered prior therapy ( except alopecia ) More 30 day since prior investigational drug No concurrent investigational agent No concurrent administration follow : Phenytoin Carbamazepine Barbiturates Rifampin Phenobarbital Hypericum perforatum ( St. John 's wort ) Systemic retinoids CYP3A4 inhibitor ( e.g. , itraconazole ) Drugs cause significant sustain elevation gastric pH ≥ 5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>